Boehringer Ingelheim and Ochre Bio Join Forces in a $1 Billion Collaboration to Combat Chronic Liver Diseases

1. Boehringer Ingelheim, a global pharmaceutical company, and Ochre Bio, a biotech firm specializing in RNA therapeutics, have entered into a $1 billion collaboration to develop new treatments for chronic liver diseases.

2. The partnership aims to leverage Ochre Bio's expertise in RNA therapeutics and Boehringer Ingelheim's experience in drug discovery and development to address unmet medical needs in liver fibrosis and non-alcoholic steatohepatitis (NASH).

3. The collaboration will focus on discovering and developing novel RNA-based therapies that can potentially slow or reverse the progression of chronic liver diseases.

4. The agreement includes an upfront payment, research funding, and potential milestone payments of up to $1 billion, subject to the successful achievement of certain development, regulatory, and commercial milestones.

5. This partnership demonstrates a significant commitment to advancing the field of RNA therapeutics and addressing the growing global burden of chronic liver diseases.